Rafael Martínez Sanz

Rafael Martínez Sanz

Auto-generated profile, based on publicly available information

Rafael Martínez Sanz

Department of Cardiovascular Surgery, Hospital Universitario de Canarias, La Laguna, Tenerife, S.C.Tenerife, Canary Islands, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2020 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
JJJuan José Jiménez-Rivera
Juan José Jiménez-Rivera
AÁAndrea Álvarez-Castillo
Andrea Álvarez-Castillo
JFJorge Ferrer-Rodríguez
Jorge Ferrer-Rodríguez
JIJosé Luis Iribarren-Sarrías
José Luis Iribarren-Sarrías
MGMartín Jesús García-González
Martín Jesús García-González
RMRafael Martínez-Sanz
Rafael Martínez-Sanz
Background: Patients with moderate-severe systolic dysfunction undergoing coronary artery bypass graft have a higher incidence of postoperative low cardiac output. Preconditioning with levosimendan may be a useful strategy to prevent this complication. In this context, design cost-effective strategies like preconditioning with levosimendan may become necessary. Methods: In a sequential assignment of patients with Left Ventricle Ejection Fraction less than 40%, two strategies were compared in terms of cost-effectiveness: standard care (n = 41) versus preconditioning with Levosimendan (n = 13). The adverse effects studied included: postoperative new-onset atrial fibrillation, low cardiac output, renal failure and prolonged mechanical ventilation. The costs were evaluated using deterministic and probabilistic sensitivity analysis, and Monte Carlo simulations were performed. Results: Preconditioning with levosimendan in moderate to severe systolic dysfunction (Left Ventricle Ejection Fraction < 40%), was associated with a lower incidence of postoperative low cardiac output in elective coronary artery bypass graft surgery 2(15.4%) vs 25(61%) (P < 0.01) and lesser intensive care unit length of stay 2(1–4) vs 4(3–6) days (P = 0.03). Average cost on levosimendan group was 14,792€ while the average cost per patient without levosimendan was 17,007€. Patients with no complications represented 53.8% of the total in the levosimendan arm, as compared to 31.7% in the non-levosimendan arm. In all Montecarlo simulations for sensitivity analysis, use of levosimendan was less expensive and more effective. Conclusions: Preconditioning with levosimendan, is a cost-effective strategy preventing postoperative low cardiac output in patients with moderate-severe left ventricular systolic dysfunction undergoing elective coronary artery bypass graft surgery.

27 September 2025 in Cirugía Cardiovascular
Verified
Journal Article
Open access
RSRafael Martínez Sanz
Rafael Martínez Sanz